166 related articles for article (PubMed ID: 32109195)
21. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
[TBL] [Abstract][Full Text] [Related]
22. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
[TBL] [Abstract][Full Text] [Related]
23. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors.
Spermon JR; Roeleveld TA; van der Poel HG; Hulsbergen-van de Kaa CA; Ten Bokkel Huinink WW; van de Vijver M; Witjes JA; Horenblas S
Urology; 2002 Jun; 59(6):923-9. PubMed ID: 12031382
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer.
Neyer M; Peschel R; Akkad T; Springer-Stöhr B; Berger A; Bartsch G; Steiner H
J Endourol; 2007 Feb; 21(2):180-3. PubMed ID: 17338618
[TBL] [Abstract][Full Text] [Related]
25. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
26. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
27. The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.
Cullen M; Huddart R; Joffe J; Gardiner D; Maynard L; Hutton P; Mazhar D; Shamash J; Wheater M; White J; Goubar A; Porta N; Witts S; Lewis R; Hall E;
Eur Urol; 2020 Mar; 77(3):344-351. PubMed ID: 31901440
[TBL] [Abstract][Full Text] [Related]
28. Management of patients with clinical stage I or II nonseminomatous germ cell tumors of the testis. Evolving therapeutic options.
Richie JP; Socinsky MA; Fung CY; Brodsky GL; Kalish LA; Garnick MB
Arch Surg; 1987 Dec; 122(12):1443-5. PubMed ID: 2446590
[TBL] [Abstract][Full Text] [Related]
29. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
30. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
Woldu SL; Moore JA; Ci B; Freifeld Y; Clinton TN; Aydin AM; Singla N; Laura-Maria K; Hutchinson RC; Amatruda JF; Sagalowsky A; Lotan Y; Arriaga Y; Margulis V; Xie Y; Bagrodia A
Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
[TBL] [Abstract][Full Text] [Related]
31. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment.
Weissbach L; Bussar-Maatz R; Flechtner H; Pichlmeier U; Hartmann M; Keller L
Eur Urol; 2000 May; 37(5):582-94. PubMed ID: 10765098
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.
Taza F; Chovanec M; Snavely A; Hanna NH; Cary C; Masterson TA; Foster RS; Einhorn LH; Albany C; Adra N
J Clin Oncol; 2020 Apr; 38(12):1338-1345. PubMed ID: 32134699
[TBL] [Abstract][Full Text] [Related]
33. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses.
Oldenburg J; Alfsen GC; Lien HH; Aass N; Waehre H; Fossa SD
J Clin Oncol; 2003 Sep; 21(17):3310-7. PubMed ID: 12947067
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
Culine S; Theodore C; Farhat F; Bekradda M; Terrier-Lacombe MJ; Droz JP
J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.
Behnia M; Foster R; Einhorn LH; Donohue J; Nichols CR
Eur J Cancer; 2000 Mar; 36(4):472-5. PubMed ID: 10717522
[TBL] [Abstract][Full Text] [Related]
37. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
38. One cycle of bleomycin, etoposide and cisplatin plus two cycles of etopeside and cisplatin chemotherapy in selected patients with low-volume stage II nonseminomatous germ cell tumor of the testis.
Mezvrishvili Z; Managadze L
Urol Int; 2005; 75(4):304-8. PubMed ID: 16327295
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant chemotherapy for stage I non-seminomatous testicular cancer.
Abratt RP; Pontin AR; Barnes RD; Reddi BV
S Afr Med J; 1994 Sep; 84(9):605-7. PubMed ID: 7530863
[TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
